Suven Life Sciences News, Corporate filings and Earnings/Conference Calls

Healthcare Services company Suven Life Sciences announced Q2FY26 results Revenue: Rs 46.97 million against Rs 66.09 million during Q2FY25. PAT: Rs -773.10 million against Rs -496.44 million during Q2FY25. EPS: Rs -3.48 for Q2FY26. Clinical development pipeline: SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of calander 2026. SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy by end of fiscal 2026. SUVN-911 (Ropanicant) – Ongoing Phase 2B clinical study in USA and expected completion by end of calander 2026. SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during 2026. SUVN-I6107 – Ongoing Phase 1 study for establishing safety and pharmacokinetics of the molecule. Anticipated completion by fiscal 2026. Result PDF

44.45% Fall from 52W High

Suven Life Sciences News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Suven Life Sciences from all sources in a single place.